EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study

Haifeng Li, Meiting Chen, Riqing Huang, Qixiang Rong, Jing Hao, Qiufan Zheng, Yanhong Su, Ditian Shu, Yue Zhang, Wei Yang, Xuefen Lei, Yuchen Cai und 3 weitere

Cancer Communications · 01.01.2026 · 46

DOI: 10.34133/cancomm.0025 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, online erschienen am 21.04.2026. Verfasst von Haifeng Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Paclitaxel, Antibodies, Monoclonal, Humanized, Albumins, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Sun Yat-sen University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor (ICI) plus nab-paclitaxel has emerged as a promising strategy for advanced urothelial carcinoma (aUC). This study investigates the efficacy and safety of camrelizumab combined with nab-paclitaxel in patients with aUC who had progressed following first-line treatment.

Methods

This multicenter, phase II study enrolled patients with aUC who had previously received at least 1 platinum-based therapy. Patients with prior ICI-based therapies were also included. Participants received 200 mg of camrelizumab on day 1 (D1) and 125 mg/m 2 of nab-paclitaxel on D1 and D8, on a 21-d cycle, until disease progression or unacceptable toxicity. The primary end point was progression-free survival (PFS). Potential biomarkers were identified through targeted gene sequencing and by quantifying pretreatment serum levels of cytokines, chemokines, growth factors, and other soluble proteins.

Results

From 2020 June 12 to 2024 April 1, a total of 60 eligible patients were enrolled. The median age was 62.5 years, 44 patients (73.33%) were male, 44 patients (73.33%) had upper tract urothelial carcinoma, and 17 patients (28.33%) received ICI-based therapies before recruitment. After a median follow-up of 27.50 months (95% confidence interval [CI], 21.90–not reached [NR]), 47 patients (78.33%) experienced disease progression. The median PFS and overall survival were 4.66 months (95% CI, 4.13 to 8.50 months) and 15.70 months (95% CI, 12.17–NR) in the full analysis set, respectively. In addition, the median PFS and overall survival were 6.45 (95% CI, 4.30 to 9.98) months and 17.98 (95% CI, 15.44–NR) months in the per-protocol set, respectively. The objective response rate was 37.04%, with 4 patients achieving complete responses and 16 patients achieving partial responses. Notably, 15 patients experienced durable responses lasting over 1 year. Adverse events of any grade occurred in 59 patients (98.33%), while grade ≥3 adverse events were reported in 31 patients (51.67%). One patient experienced immune-related pneumonia. Biomarker analyses suggested that the elevated pretreatment serum levels of cluster of differentiation 25, interleukin-6, and insulin-like growth factor binding protein 2 were associated with worse treatment responses.

Conclusions

Camrelizumab plus nab-paclitaxel demonstrated modest antitumor activity along with manageable toxicity in patients with previously treated aUC.

Trial registration

This trial was registered at www.chictr.org.cn (Identifier: CTR2000033820, registration date: 2020 June 13).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelAntibodies, Monoclonal, HumanizedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsUrologic NeoplasmsCarcinoma, Transitional CellHumansMaleFemaleMiddle AgedAgedProgression-Free Survival

Substanzen

PaclitaxelAntibodies, Monoclonal, Humanized130-nm albumin-bound paclitaxelAlbuminscamrelizumab

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China.
  • Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510060, P. R. China.
  • Department of Medical Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, P. R. China.

Förderung

  • National Natural Science Foundation of China
  • Sun Yat-sen University

Zitieren

APA

Li, H., Chen, M., Huang, R., Rong, Q., Hao, J., Zheng, Q., Su, Y., Shu, D., Zhang, Y., Yang, W., Lei, X., Cai, Y., Xue, C., An, X., & Shi, Y. (2026). Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0025

Vancouver

Li H, Chen M, Huang R, Rong Q, Hao J, Zheng Q, et al. Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study. Cancer Communications. 2026;46. doi:10.34133/cancomm.0025

BibTeX
@article{Li2026,
  author = {Li, Haifeng and Chen, Meiting and Huang, Riqing and Rong, Qixiang and Hao, Jing and Zheng, Qiufan and Su, Yanhong and Shu, Ditian and Zhang, Yue and Yang, Wei and Lei, Xuefen and Cai, Yuchen and Xue, Cong and An, Xin and Shi, Yanxia},
  title = {Camrelizumab Plus Nab-paclitaxel in Patients with Previously Treated Advanced Urothelial Carcinoma: A Multicenter Phase II Study},
  journal = {Cancer Communications},
  year = {2026},
  volume = {46},
  doi = {10.34133/cancomm.0025}
}
Kostenlos starten →